Interstitial Lung Disease

Receiving admilparant, an oral lysophosphatidic acid receptor 1 antagonist, for 26 weeks lowered percent-predicted FVC decline in idiopathic and progressive pulmonary fibrosis, according to study results.

Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast, an investigational phosphodiesterase 4B inhibitor, vs. placebo, according to FIBRONEER-ILD topline results.

Treatment with TNF inhibitors yielded no differences in outcomes vs. other antirheumatic therapies among U.S. veterans with rheumatoid arthritis-associated interstitial lung disease, according to data published in The Lancet Rheumatology.

Receiving a diagnosis for any disease/condition is not an easy experience. One organization hopes to make patients newly diagnosed with pulmonary fibrosis feel supported during this time via a new online educational resource.

Patients with rheumatoid arthritis who demonstrate consistent long-term elevation of inflammatory markers have an increased risk for interstitial lung disease, according to data published in Arthritis Research & Therapy.

Patients with idiopathic pulmonary fibrosis had less FVC decline between baseline and 26 weeks with receipt of three daily doses of 825 mg deupirfenidone, according to phase 2b ELEVATE IPF trial results.

WASHINGTON — Patients with systemic autoimmune rheumatic disease who develop interstitial lung disease demonstrate similar 1-year mortality risks following either single- or double-lung transplant, according to data.

EULAR has released new recommendations on the treatment of systemic sclerosis, advancing new treatments and updated approaches to key manifestations such as skin and lung fibrosis.

WASHINGTON — Healio spoke with Jeffrey A. Sparks, MD, MMSc, about baseline results from the SAIL-RA study, which assesses which patients with rheumatoid arthritis may be at risk for developing interstitial lung disease.

BOSTON — To help patients with interstitial lung disease lower the chances of having a sick baby, physicians must have “honest and accurate conversations” with them before pregnancy, according to a presentation at the CHEST Annual Meeting.